certain populations; increasing the effectiveness and reach of ARV programmes across the continuum of
care through a strategic mix of quality-assured HIV testing approaches, improving adherence and retention, innovative service delivery, integrating ART in a wider range of settings and strengthening links between services; and engaging in both short and longer-term efforts to optimize and harmonize drug regimens and increase their affordability and to develop and implement simpler and more affordable point-of care diagnostics and laboratory services (Essajees,etal ,2015)
Promoting human rights and health equity
Access to HIV prevention, treatment, care and support should be recognized as fundamental to realizing the universal right to health, and these guidelines should be implemented based on core human rights and ethical principles.
Adoption and Implementation of National Antiretroviral Treatment (ART) guideline
The guidelines offer the following anticipated benefits:
1. Guidance on using ARV drugs is presented within the context of the continuum of HIV-related prevention, treatment and care. In addition to providing recommendations on the clinical use of ARV drugs for treatment, the guidelines address other major aspects of HIV-related care.
2. The guidelines address the use of ARV drugs for all age groups and populations. Previously separate National guidelines on using ART among adults and adolescents have been combined with those for children and for PMTCT, harmonizing ARV regimens and treatment approaches to the extent possible across age groups and populations. New and existing guidance is harmonized. Consolidation has allowed for new recommendations to be harmonized with relevant, existing WHO guidance (WHO 2014) .
3. Consolidation promotes the consistency of approaches and linkage between settings. Consolidated recommendations help to facilitate linkage and promote consistency of approaches across the various settings in which ARV drugs and related services may be provided, including specialized HIV care, primary care, community-based care, maternal and child health services, TB services and services for people who use drugs.
4. Updates will be more timely and comprehensive. Consolidated guidelines enable key clinical, operational and programmatic implications of new science and emerging practice in the use of ARV drugs (FMOH 2014 and WHO, 2010)
Objectives of the guidelines
1. To provide updated, evidence-based clinical recommendations outlining a public health approach to providing ARV drugs for HIV treatment and prevention in the context of the continuum of HIV care in the comprehensive HIV/AIDS service delivery setting.
2. To provide guidance on key operational and service delivery issues that need to be addressed to increase access to HIV services, strengthen the continuum of HIV care and further integrate the provision of ARV drugs into health systems; and to serve as a reference material for health service providers and program managers
1. Health care workers (physicians, health officers, nurses, pharmacy personnel, laboratory technicians and case managers) providing care to people infected and affected with HIV
2. HIV/AIDS program managers, health planners and researchers .Organizations involved in antiretroviral drug procurement, supply management, and ART service delivery.
3. Community based organizations and Faith based organizations working on HIV
1. Consolidated guidelines on HIV testing services. Geneva: World Health Organization; 2015
2. WHO information note – 22 October 2014. Geneva: World Health Organization; 2014
3. Harrison’s Principles of Internal Medicine 19th edition, 2015
4. FMOH, National Guidelines for Comprehensive HIV Prevention, Care and Treatment. Federal Ministry of Health, Ethiopia; 2014
5. HIV and adolescents: guidance for HIV testing and counselling and care for adolescents living with HIV. Geneva: World Health Organization; 2014
6. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013
7. UNAIDS. Global AIDS Response Progress Reporting 2015
8. Essajee S, Vojnov L, Penazzato M, Jani I, Siberry G, Fiscus R et al. Reducing mortality in HIV-infected infants and achieving the 90.90.90 target through innovative diagnoses approaches. J Int AIDS Soc. 2015, 18 (Suppl 6):20299.
9. WHO recommendations on the diagnosis of HIV infection in infants and children. Geneva: World Health Organization; 2010
10. “About ONAP”. Office of National AIDS Policy. White House 2010.